Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

BUY
$23.37 - $32.96 $8,693 - $12,261
372 Added 1.93%
19,597 $578 Million
Q1 2023

Apr 24, 2023

BUY
$21.91 - $32.67 $21,055 - $31,395
961 Added 5.26%
19,225 $443 Million
Q4 2022

Feb 16, 2023

BUY
$26.28 - $33.92 $479,977 - $619,514
18,264 New
18,264 $508 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Linden Thomas Advisory Services, LLC Portfolio

Follow Linden Thomas Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Linden Thomas Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Linden Thomas Advisory Services, LLC with notifications on news.